<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02439359</url>
  </required_header>
  <id_info>
    <org_study_id>CF 301-101</org_study_id>
    <nct_id>NCT02439359</nct_id>
  </id_info>
  <brief_title>A Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Male and Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ContraFect</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ContraFect</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1, Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability&#xD;
      of Single Intravenous Doses of CF-301 in Healthy Subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability as measured by AE's</measure>
    <time_frame>up to 8 months</time_frame>
    <description>Safety and tolerability will be assessed by monitoring AEs and performing physical/clinical examinations.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CF-301</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CF-301</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CF-301</intervention_name>
    <description>Dose escalation</description>
    <arm_group_label>CF-301</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be a healthy male of any race or ethnicity, at least 18 years of age and no more than&#xD;
             55 years of age, inclusively, OR&#xD;
&#xD;
          2. Be a healthy female of any race or ethnicity of non-childbearing potential between 18&#xD;
             and 55 years of age, inclusive. OR&#xD;
&#xD;
          3. Be a healthy non-pregnant, non-lactating female of any race or ethnicity of&#xD;
             childbearing potential between 18 and 55 years of age,&#xD;
&#xD;
          4. Contraception in use for at least 60 days prior to the Screening visit,&#xD;
&#xD;
          5. Have a body mass index (BMI) between 18.5 and 32 kg/m2, inclusive&#xD;
&#xD;
          6. Have no significant diseases in the opinion of the Investigator in the medical history&#xD;
             or clinically significant findings on physical examination or clinical laboratory&#xD;
             evaluations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any disease or condition in the opinion of the Investigator that might compromise the&#xD;
             cardiovascular, hematologic, renal, hepatic, pulmonary (including chronic asthma),&#xD;
             endocrine (eg, diabetes), central nervous, or gastrointestinal (including an ulcer)&#xD;
             systems.&#xD;
&#xD;
          2. The presence of clinically significant laboratory values that are out of the normal&#xD;
             range.&#xD;
&#xD;
             - Subjects with an aspartate aminotransferase (AST), alanine aminotransferase (ALT),&#xD;
             gamma-glutamyltransferase (GGT), alkaline phosphatase, bilirubin, blood urea nitrogen&#xD;
             (BUN), creatinine, prothrombin time (PT), or activated partial thromboplastin time&#xD;
             (aPTT) &gt; 5% above the upper limit of normal, or hemoglobin or hematocrit level &lt; 5%&#xD;
             below the lower limit of normal may not be enrolled.&#xD;
&#xD;
          3. A history of alcoholism or drug addiction, or illicit drug use within the past 2&#xD;
             years, or positive results from a urine screen for substances of abuse.&#xD;
&#xD;
          4. Has smoked within 28 days prior to receiving study drug or has a positive urine test&#xD;
             for cotinine.&#xD;
&#xD;
          5. A history of serious mental illness.&#xD;
&#xD;
          6. A history of difficulty donating blood or inadequate venous access.&#xD;
&#xD;
          7. The donation of blood or plasma within 28 days prior to receiving study drug.&#xD;
&#xD;
          8. A positive hepatitis screen that tests for both hepatitis B surface antigen (HBsAg)&#xD;
             and antibody to hepatitis C virus (HCVAb).&#xD;
&#xD;
          9. A positive test result for human immunodeficiency virus (HIV) antibody by enzyme&#xD;
             immunoassay, which is confirmed by Western blot.&#xD;
&#xD;
         10. Use of an investigational drug or product, or participation in a drug study within a&#xD;
             period of 28 days prior to receiving study drug (for investigational drugs with an&#xD;
             elimination half-life greater than 10 days, this will be extended to 60 days).&#xD;
&#xD;
         11. Use of any prescription or over-the-counter (OTC) drug therapy, including herbal,&#xD;
             homeopathic, vitamins, minerals and nutritional supplements, within 2 weeks prior to&#xD;
             receiving the study drug contraceptives in women of childbearing potential is allowed&#xD;
             during the study.&#xD;
&#xD;
             - If a subject taking prescription drug therapy for chronic diseases, but that&#xD;
             prescription is stopped in order to qualify for the study, the subject should not be&#xD;
             enrolled in the study.&#xD;
&#xD;
         12. Use of any drug therapy (ie, prescription drugs, over-the counter products, herbal and&#xD;
             vitamin products) known to induce or inhibit cytochrome P450 hepatic enzymes&#xD;
             responsible for drug metabolism within 28 days prior to receiving study drug or during&#xD;
             the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cf 301-105</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>April 27, 2015</study_first_submitted>
  <study_first_submitted_qc>May 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2015</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Sepsis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Public Presentation at ECCMID April 2016</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

